China's pharmaceutical industry is made up of five sub-sectors (Table 16. 1985 1987 1989 1991 1993 1995 1997 1999 2001 Sources: China State Statistical Bureau, China Statistical Yearbook, 1986 -2002 Beijing, China Statistical Publishing House. 1991 1992 1993 1994 1995 1996 1997 1998 1999 
16.3).
During 1992-95, the export value of medicines rose sharply, growing at an annual average rate of 20.1 per cent. In contrast, the import value of medicines fell by 14.4 per cent. Since 1997, however, the import value of medicines has increased rapidly, growing at an annual average rate of 38.5 per cent.
Although the Chinese pharmaceutical industry as a whole has been growing rapidly, small-scale industries that are widely dispersed are the main characteristics of Chinese pharmaceutical enterprises. At present, there are 3,488 pharmaceutical In the field of traditional Chinese medicine, the 'Gingko pill' and 'Salvia miltiorrhiza pill' have passed the US Federal Drug Administration's (FDA) antecedent examination, and are now in the clinical test stage. The export value of traditional Chinese medicines from China accounted for only 3 per cent of the total sales revenue generated by Chinese medicines on the international market. In the field of 
INTERNATIONAL TRADING COMPETITIVENESS Measuring international trading competitiveness
The trading competitiveness of pharmaceutical products can be measured using the international trading competitive index and the price index. The international trading competitiveness index can be calculated using the following formula and definition
International trading competitiveness index = (export value -import value)/ (export value + import value)
International trading competitiveness scores close to 1 indicate high trading competitiveness, and scores closer to zero indicate low trading competitiveness.
Where the total international trading competitiveness index of overall products in particular industry is negative, this industry has a lack of international trading competitiveness, and a deficit of foreign trade occurs.
The price index has the following calculation formula and definition, Price index = (export value/export volume) / (import value/import volume)
The price index reflects the unit parity of a product in the international market. 
POTENTIAL TRADING COMPETITIVENESS
Potential trading competitiveness depends mainly on an industry's innovative ability.
The number of patents is a crucial indicator of the innovation of the pharmaceutical industry. According to International Patent Classification (IPC), patents related to the pharmaceutical industry are mainly in the categories of Medicine A61 K and its subgroups-Chemical Medicine A61 K31, Traditional Chinese Medicine A61 K35 and Pharmaceuticals A61 K9. Table 16 .5 is an analysis of medicine patent applications, and Figure 16 .4 presents the ratio of patents for Chinese medicine applications granted to Chinese and to foreign applicants.
In traditional Chinese medicine, the proportion of patents granted to foreign applicants reached its highest level in 1994 (10 per cent). Since then th proportion has been very low (Table 16. .. Within three years of China's accession to the WTO, the applied average tariff rate of imported pharmaceuticals will be reduced by 5-6 per cent (see Annex 8-Schedule CLlI" of the Protocol on Accession). After accession to the WTO, Chinese authorities were to adopt a number of administrative measures.
.. Pharmaceuticals subject to state pricing covered HS numbers 30011000 to 30066000, including substances of human or animal origin, heparin and its salts, antisera, other blood fractions and modified immunological products, patents. This will have detrimental effects not only on pharmaceutical enterprises that were producing imitations of patented pharmaceuticals, but also on business opportunities for foreign pharmaceutical firms in China.
Consumer demand for pharmaceutical products
Consumer demand for pharmaceuticals in China is very large. It is estimated that consumer demand for pharmaceuticals will reach 336 billion yuan by 2005, 1.7 times more than in 2001.
A series of factors underlie such a huge increase in demand.
.. China has the largest population in the world. The population will reach 1.33 billion by 2005.
• Although the industry has a certain degree of competitive advantage in price, its international trading competitiveness is seriously diminishing.
Business opportunities
Foreign pharmaceutical manufacturers can capture good business opportunities by establishing wholly foreign-owned pharmaceutical factories and producing pharmaceuticals with autonomic patent rights. However, this requires a large initial investment and further costs to open up the market. Another way is to purchase and merge existing pharmaceutical enterprises, and to produce autonomic patented pharmaceuticals. At present, local governments are selling and auctioning stateowned enterprises within their jurisdiction. Depending on foreign enterprises' bargaining power with local governments, merger and acquisitions could be a lowercost strategy for entering the market.
Setting up a wholly foreign-owned pharmaceutical company or a distributing network is an efficient way to enter the market. This strategy, however, requires large investments, bears a high cost for the developing market and has certain risks.
There are still uncertainties about permission for foreign service suppliers to engage in distribution of pharmaceuticals. To purchase and merge existing pharmaceutical companies and restructure them with an advanced management structure would be another low cost way to enter the pharmaceutical market.
Profitable fields
What would be a profitable field for a foreign pharmaceutical firm to invest in?
Currently there are shortages of special intermediates for preparing pharmaceuticals, such as 6-aminopenlcilianic acid (6-APA), 7-aminocephalosporianic acid (7-ACA), 7-aminodeacetoxycefanoic acid (7-ADCA), isophytol and trimethylhydroquinone. The production of these intermediates would be profitable. Current technologies for pharmaceutical preparation are also outdated. The production of new sustained-release and controlled-release medicaments, as well as targeting and transdermal delivery of medicaments, would also be profitable.
The production of biopharmaceuticals is just beginning, so the biopharmaceutical production of antisera, other blood fractions and modified immunological products, vaccines, toxins prepared for diagnostiCS, prophylactics, therapeutics for malignant tumours and for cardiovascular and cerebrovascular diseases, diseases of the central nervous system, respiratory system, digestive system, and for AIDS and other immunodeficiency diseases would be highly profitable.
China has abundant resources for preparing natural pharmaceuticals. There are 12,807 species of plants, minerals and animals. However, the techniques for preparing natural pharmaceuticals are primitive. Using the advanced techniques of extraction, purification and separation to produce natural pharmaceuticals would be very profitable.
CONCLUDING REMARKS
Accession to the WTO has further integrated the Chinese economy into the global economic system, with an accelerated pace of industrial restructuring and increased business opportunities for foreign pharmaceutical firms now appearing in China. In order to explore and capture these opportunities, and to enter more profitable fields, foreign firms need to pay attention in number of factors.
.. Although China has formally become a member of WTO, the administrative measures adopted by governments are still not fully transparent. This will create uncertainties for foreign firms intending to capture business opportunities in the pharmaceutical industry.
. Hope lies in strict implementation of China's WTO commitments-opening up China's market and creating an environment in which both domestic and foreign firms can compete on an equal footing.
